Skip to main content
FibroBiologics, Inc. logo

FibroBiologics, Inc. — Investor Relations & Filings

Ticker · FBLG ISIN · US31573L1052 LEI · 5493000KQEGHXVWRMZ92 US Manufacturing
Open in API
Filings indexed 189 across all filing types
Latest filing 2026-05-06 Capital/Financing Update
Country US United States of America
Listing US FBLG

About FibroBiologics, Inc.

https://fibrobiologics.com/

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast cell-based therapies for chronic diseases. The company utilizes the regenerative and immune-modulating properties of fibroblasts, the primary cell type in connective tissue, to create treatments for conditions where there is a significant unmet medical need. Its development pipeline targets multiple sclerosis, degenerative disc disease, and wound healing. FibroBiologics is also advancing a bone marrow organoid platform for potential applications in cancer and immune-related therapies. The company's research and development are supported by an intellectual property portfolio of over 160 issued patents.

Recent filings

Filing Released Lang Actions
8-K - FibroBiologics, Inc. (0001958777) (Filer)
Capital/Financing Update Classification · 90% confidence The document is a Form 8-K “Current Report” disclosing the entry into a material definitive agreement for an At-the-Market Offering (ATM), the filing of a prospectus supplement to increase the maximum share offering, and related issuance of shares. This is an update on the company’s financing activities and capital structure. It is not a full annual or interim report, nor is it solely a legal or governance disclosure. Therefore, it best fits the “Capital/Financing Update” category.
2026-05-06 English
8-K - FibroBiologics, Inc. (0001958777) (Filer)
Remuneration Information Classification · 87% confidence The document is a Form 8-K current report, Section 5.02, disclosing compensatory arrangements (stock option grants) for the CEO, CFO, CSO and GC. It does not contain full financial statements or voting results, nor is it merely announcing the publication of another report. It purely details executive compensation arrangements, which aligns with the Remuneration Information category (DEF 14A).
2026-05-05 English
ARS - FibroBiologics, Inc. (0001958777) (Filer)
Annual Report
2026-05-05 English
DEF 14A - FibroBiologics, Inc. (0001958777) (Filer)
Proxy Solicitation & Information Statement
2026-05-05 English
424B5 - FibroBiologics, Inc. (0001958777) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an At The Market Offering Agreement for common stock of FibroBiologics, Inc. It details the terms of a stock offering, including the sales agreement, pricing, reverse stock split, and use of proceeds. The document is a registration and offering document related to capital raising activities, not a financial report, earnings release, or management discussion. It is not a report publication announcement or a regulatory filing in the sense of certifications or attestations. The content clearly fits the definition of a Capital/Financing Update, as it provides updates on company fundraising and capital structure changes through a stock offering prospectus supplement.
2026-05-01 English
8-K - FibroBiologics, Inc. (0001958777) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 1, 2026, by FibroBiologics, Inc. It announces the entry into a material definitive agreement, specifically an At The Market Offering Agreement for issuing and selling common stock up to $6,150,000. The content focuses on the financing arrangement and details of the sales agreement with the sales agent. There are no financial statements or quarterly/yearly financial results presented, nor is it a transcript, proxy, or governance report. The primary purpose is to update on a capital raising activity. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing agreement, not just an announcement of a report or certification, so it is not RPA or RNS. Confidence is high due to clear identification of the filing type and content.
2026-05-01 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.